Pharma Antes Up: Investment and Business Trends Driving Biotechnology

Published by: Decision Resources

Published: Jun. 15, 2007 - 27 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Lead Development Deals

Pharma-Biotech

Biotech-Biotech

Lead Optimization Deals

Lead Identifi cation Deals

Pharma-Biotech

Biotech-Biotech

Target Identifi cation and Validation Deals

Mergers and Acquisitions

Pharma-Biotech

Biotech-Biotech

Reverse Mergers

Outlook: 2007 and Beyond

Tables:

1.Select Pharma-Biotech Lead Development Deals with Values More Than $200 Million

2. Select Biotech-Biotech Lead Development Deals with Values More than $100 Million

3. Select Lead Optimization Deals

4. Select Lead Identifi cation Deals

5. Select Target Identifi cation and Target Validation Deals

6. Select Mergers and Acquisitions

Figures:

1. All Life Science Mergers and Acquisitions

2. Number of Pharma-Biotech and Biotech-Biotech Mergers and Acquisitions Valued at More Than $100 Million, 2002-2006

3. Total Value of Pharma-Biotech and Biotech-Biotech Mergers and Acquisitions Valued at More Than $100 Million, 2002-2006

4. Cyclical Nature of the Value of Platform Technologies

Abstract

• Big Pharma has expressed renewed interest in platform technologies and early-stage clinical candidates originating from biotechnology companies. What types of deals are occurring most frequently between these industries? What approaches to drug discovery are of most interest to pharmaceutical companies? What clinical trial phase is receiving the most attention from Big Pharma?
• In addition to the growing interest from pharmaceutical companies, many biotechs are also now participating in high-value partnerships with other biotechs to fund drug development. How do biotech-biotech deals differ from those involving Big Pharma? In what ways do biotech companies’ long-and short-term goals correspond to or differ from those of pharmaceutical companies?
• Consolidation of the pharmaceutical and biotech industries has continued, with a recent surge in the number of mergers and acquisitions. What resources do pharmaceutical companies look for in companies when they consider acquisitions? What platforms or indications have been highlighted as areas of interest by Big Pharma? What does the emergence of reverse mergers say about the state of the market?
• As the biotechnology industry continues to mature, biotech companies will face more and more of the issues that typically plague Big Pharma. What are the key issues that biotech companies will face as they mature? How will these issues impact the risk and success of biotech drug development?

• Deal activity, by drug discovery stage: a review of deals for compounds in lead development; lead optimization; lead identification; and target identification and validation.
• Mergers and acquisitions: a review of high-value ($100 million+) M&A deals involving biotech, including a look at reverse mergers.
• Deal participants: an examination of pharma-biotech and biotech-biotech deal activity.
• Market outlook: our forecast for trends in biotech dealmaking for 2007 and beyond.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.